Cargando…
Virtual screening and experimental validation of novel histone deacetylase inhibitors
BACKGROUND: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clinical applications. Increasing...
Autores principales: | Huang, Yan-xin, Zhao, Jian, Song, Qiu-hang, Zheng, Li-hua, Fan, Cong, Liu, Ting-ting, Bao, Yong-li, Sun, Lu-guo, Zhang, Li-biao, Li, Yu-xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955146/ https://www.ncbi.nlm.nih.gov/pubmed/27443303 http://dx.doi.org/10.1186/s40360-016-0075-8 |
Ejemplares similares
-
Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression
por: Wang, Jiayu, et al.
Publicado: (2022) -
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020) -
Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice
por: Li, Xiaohua, et al.
Publicado: (2019) -
Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach
por: Hsu, Kai-Cheng, et al.
Publicado: (2017) -
Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)